National Health Service Recommends Assessment for Elevated Protease Activity Using Diagnostic Test to Help Decide Venous Leg Ulcers Treatment Pathway, Reports Systagenix

GATWICK, England--(BUSINESS WIRE)--Developed by National Health Service (NHS) commissioners, clinical experts and Department of Health officials and intended to drive improvements in the way in which leg ulcer services deliver care to patients, the recently released service specification1, intended for use by NHS commissioners, clearly identifies elevated protease activity (EPA) as a complication known to reduce healing rates and increase the duration for wound healing.